Knetki-Wróblewska, M.; Tabor, S.; Piórek, A.; Płużański, A.; Winiarczyk, K.; Zaborowska-Szmit, M.; Zajda, K.; Kowalski, D.M.; Krzakowski, M.
Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. J. Clin. Med. 2023, 12, 2409.
https://doi.org/10.3390/jcm12062409
AMA Style
Knetki-Wróblewska M, Tabor S, Piórek A, Płużański A, Winiarczyk K, Zaborowska-Szmit M, Zajda K, Kowalski DM, Krzakowski M.
Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. Journal of Clinical Medicine. 2023; 12(6):2409.
https://doi.org/10.3390/jcm12062409
Chicago/Turabian Style
Knetki-Wróblewska, Magdalena, Sylwia Tabor, Aleksandra Piórek, Adam Płużański, Kinga Winiarczyk, Magdalena Zaborowska-Szmit, Katarzyna Zajda, Dariusz M. Kowalski, and Maciej Krzakowski.
2023. "Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice" Journal of Clinical Medicine 12, no. 6: 2409.
https://doi.org/10.3390/jcm12062409
APA Style
Knetki-Wróblewska, M., Tabor, S., Piórek, A., Płużański, A., Winiarczyk, K., Zaborowska-Szmit, M., Zajda, K., Kowalski, D. M., & Krzakowski, M.
(2023). Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. Journal of Clinical Medicine, 12(6), 2409.
https://doi.org/10.3390/jcm12062409
